A Study of Duloxetine in the Treatment of Fibromyalgia

Lilly

Status and phase: Completed; Phase 3

Conditions: Fibromyalgia

Treatments: Drug: duloxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00125892

F1J-MC-HMEH

9075

Details and patient eligibility

About

This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists

Exclusion criteria

• Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study.
• Any patients judged by their physicians to be at serious suicidal risk.
• Have uncontrolled narrow-angle glaucoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind